Philips expands its home care portfolio for COPD patients with first-of-its-kind non-invasive ventilator
November 04 2020 - 8:00AM
Philips expands its home care portfolio for COPD patients with
first-of-its-kind non-invasive ventilator
November 4, 2020
- Connected BiPAP A40 EFL ventilator is the first to help
healthcare professionals screen, detect, and abolish expiratory
flow limitation to reduce work of breathing in COPD patients with
abnormally elevated blood carbon dioxide levels
- BiPAP A40 EFL leverages Philips leading connected solution
platform to streamline diagnostic work through integration to
Philips Alice sleep lab and home diagnostic systems
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced
the launch of Philips Ventilator BiPAP A40 EFL. With the
introduction of this non-invasive ventilator, Philips extends its
homecare solutions with a new ventilation therapy feature for
chronic obstructive pulmonary disease (COPD) patients to breathe
easier. Now, pulmonologists can identify COPD patients with
expiratory flow limitation (EFL) and treat them with targeted
therapy to reduce symptoms and increase their comfort while
sleeping. The BiPAP A40 EFL ventilator continuously and optimally
adjusts pressure based on patient needs [1, 2].
BiPAP A40 EFL is the first and only non-invasive ventilator that
allows health care professionals to automatically screen for and
detect EFL, then provide optimal homecare therapy to dynamically
and automatically abolish EFL [1]. This helps to reduce the
patient’s work of breathing. Built with Philips proprietary and
clinically validated ExpiraFlow technology, BiPAP A40 EFL is
designed to connect across the care pathway – from diagnostic work
to point of care therapy – to enable informed clinical decisions
and optimize ventilation therapy, even remotely.
More than 50 percent of COPD patients experience EFL – limited
exhalation of breath from the lungs – which occurs in the lower
airways when patients are breathing quietly [2]. EFL causes
hyperinflation, or breathing at increased lung volumes. COPD
patients with EFL are more likely to be hospitalized more often and
have increased mortality rates, however EFL is difficult to detect
and often undertreated, despite its prevalence. Philips unique
ExpiraFlow technology automatically detects EFL more accurately
than any alternate methods [3] to enable the more effective
treatment of patient in the home and help avoid hospital
readmissions [2].
“ExpiraFlow Technology represents a shift in the paradigm
of ventilator COPD management toward more personalized therapy,
which automatically optimizes ventilation to the individual needs
of the patient,” said Peter Calverley, Professor of Respiratory
Medicine, School of Aging and Chronic Disease at the University of
Liverpool. “By monitoring the presence of EFL on a breath-by-breath
basis, the A40 EFL system can automatically adjust therapy
pressures to ensure efficient lung emptying and better gas
exchange. This new focus allows us to consider individual
differences in lung mechanics and gas exchange when managing
complex respiratory patients.”
“EFL often goes undetected, meaning patients don’t receive the
care they need to improve their disease,” said Eli Diacopoulos,
Respiratory Care Business Leader at Philips. “At Philips, we’re
committed to identifying these gaps and meeting the challenges that
COPD patients face every day. BiPAP A40 EFL aims to revolutionize
COPD care solutions. Clinicians can now detect EFL in hypercapnic
COPD patients at the point of care, ensure personalized patient
treatment at home and monitor care remotely.”
The BiPAP A40 EFL leverages Philips leading connected solution
platform to streamline diagnostic work through integration to
Philips Alice sleep lab and home diagnostic systems. When
prescribed and used in the home, the BiPAP A40 EFL connects to
Philips Care Orchestrator cloud-based care management system. By
making it easier to analyze and share information [4], this
connectivity enables providers to make faster, more informed
clinical decisions, and identify and prioritize patients who are in
need of therapy intervention to better manage chronic respiratory
patient care from hospital to home.
BiPAP A40 EFL is CE marked and initially available for sale in
selected countries in Europe [5], with expansion in to additional
European markets expected in 2021. This solution is not available
in the United States. For more information on Philips Ventilator
BiPAP A40 EFL, visit www.philips.com/targetEFL.
[1] ES Suh1, P. P. (2014). Abolition of expiratory flow
limitation in severe COPD using auto-titrating CPAP based on the
measurement of within-breath airway reactance determined by the
forced oscillation technique. ATS Poster, 1.[2] Aarli, B. B.,
Calverley, P. M., Jensen, R. L., Dellacà, R., Eagan, T. M., Bakke,
P. S., & Hardie, J. A. (2017). The association of tidal EFL
with exercise performance, exacerbations, and death in COPD.
International journal of chronic obstructive pulmonary disease, 12,
2179[3] Calverley, Dellaca, Non-invasive Screening of Expiratory
Flow Limitation in Chronic Obstructive Pulmonary Disease. European
Respiratory and Pulmonary Diseases. 2018;4(suppl. 1):3-6[4] Key
ventilation parameters, alarm data, device performance and patient
usage.[5] France, Italy and the United Kingdom
For further information, please contact:
Meredith Amoroso Philips Global Press Office Mobile: +1
724-584-8991 Tel: meredith.amoroso@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2019 sales of EUR 19.5 billion and
employs approximately 81,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- A patient is setup on Philips Ventilator BiPAP A40 EFL
- Philips Ventilator BiPAP A40 EFL aims to abolish EFL
automatically
- Philips Ventilator BiPAP A40 EFL
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024